FRATES JAMES M 4
4 · Amylyx Pharmaceuticals, Inc. · Filed Mar 9, 2026
Research Summary
AI-generated summary of this filing
Amylyx (AMLX) CFO James Frates Receives RSU Awards
What Happened
- James M. Frates, Chief Financial Officer of Amylyx Pharmaceuticals (AMLX), received stock awards on March 5, 2026. The filing reports two grant-type transactions: 95,990 shares (award) and 143,985 derivative award shares, both reported at $0.00 per share (these are grants/RSUs, not open-market purchases).
Key Details
- Transaction date: March 5, 2026; Form 4 filed March 9, 2026.
- Reported consideration: $0.00 per share (award/grant).
- Total shares granted: 239,975 RSU-type units (95,990 + 143,985).
- Shares owned after transaction: Not specified in the excerpt of the filing provided.
- Notable footnotes from the filing:
- F1: The RSUs vest in four equal annual installments; first vesting date is March 1, 2027, subject to continued service.
- F2–F4: Certain shares are held in trusts (2025 GRAT, 2024 GRAT, and a family irrevocable trust) for which Frates is trustee; he disclaims beneficial ownership except to the extent of any pecuniary interest.
- F5: Describes a separate option vesting schedule (25% vesting on March 1, 2027, remainder monthly over 36 months) — included in the filing notes.
- Filing timeliness: The report was filed March 9, 2026 for transactions dated March 5, 2026; the filing itself does not state a late-filing designation.
Context
- These entries are awards (RSUs/derivative RSUs). RSUs convert into common shares only as they vest; they are not immediate purchases or sales. Awards and trust transfers are often part of executive compensation and do not by themselves indicate a buy or sell market signal.
Insider Transaction Report
Form 4
FRATES JAMES M
Chief Financial Officer
Transactions
- Award
Common Stock
[F1]2026-03-05+95,990→ 261,628 total - Award
Stock Option (right to buy)
[F5]2026-03-05+143,985→ 143,985 totalExercise: $14.10Exp: 2036-03-05→ Common Stock (143,985 underlying)
Holdings
- 100,000(indirect: By Trust)
Common Stock
[F2] - 15,459(indirect: By Trust)
Common Stock
[F3] - 11,072(indirect: By Trust)
Common Stock
[F4]
Footnotes (5)
- [F1]The reported transaction involves the Reporting Person's receipt of a restricted stock unit ("RSU") award. The RSUs shall vest in 4 equal annual installments, with the first installment vesting on March 1, 2027, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
- [F2]Shares held by the JAMES M. FRATES 2025 GRAT NO 1 U/A DTD 12/12/2025, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
- [F3]Shares held by the James M. Frates 2024 Grantor Retained Annuity Trust No. 1, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
- [F4]Shares held by the FRATES FAMILY 2013 IRREV TRUST, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
- [F5]25% of the shares subject to the option shall vest and become exercisable on March 1, 2027, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.
Signature
/s/ Joshua B. Cohen, as Attorney in Fact|2026-03-09